Back to search

The University of Edinburgh

Defining novel regulators of inflammatory signalling in pancreatic cancer

Abstract

dc:description.abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a cancer with few effective therapeutic options and, for patients with this disease, the prognosis remains extremely poor. In recent years immunotherapy has emerged as a promising treatment modality for a number of different tumour types but so far its impact in treatment of PDAC has been limited. Examining the molecular pathways that determine the immune response to cancer cells in PDAC will enable development of new therapeutic strategies to target this response. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is elevated in human PDAC tissues and correlates with high levels of fibrosis and poor CD8+ T cell infiltration. The Serrels Laboratory has already demonstrated a role for FAK in promoting tumour evasion by inducing an immunosuppressive microenvironment, specifically by regulation of cytokines. This has led to trials of the FAK inhibitor (defactinib) in conjunction with immunotherapy. I proposed that FAK was likely to regulate further chemokine/cytokine and ligand receptor networks and that by understanding more about these networks it may be possible to target potential pathways to modify this response and provide therapeutic benefit. I used CRISPR, Forward Phase Protein Arrays (FPPA) and ELISA on mouse and human PDAC cell lines to examine relative expression of chemokines and cytokines and how this expression was regulated by FAK. I identified CXCL16 as one of the most abundantly expressed cytokines in both mouse and human cell lines and one of the most significantly increased cytokines upon FAK depletion. PDAC FAK null cell lines +/- CXCL16 were then orthotopically implanted into the pancreas of C57BL/6 mice and I demonstrated that CXCL16 depletion resulted in a re-programming of the immune cell tumour infiltrate with reduced tumour growth. These findings identify a FAK dependent CXCL16-CXCR6 paracrine signalling axis that may represent a mechanism of resistance to FAK inhibition and thus an important potential therapeutic target.

Degree

thesis:*
Grantor dc:publisher
The University of Edinburgh
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Parry, Jane Louise
Advisors dc:contributor.advisor
  • Serrels, Alan
  • Pollard, Steven

Subjects

dc:subject × 15

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Parry, Jane Louise. Defining novel regulators of inflammatory signalling in pancreatic cancer. The University of Edinburgh, 2024. https://hdl.handle.net/1842/41367